IRVINE, Calif., Sept. 5, 2012 /PRNewswire/ -- AtheroNova Inc. (OTCBB: AHRO) ("AtheroNova"), a biotech company focused on the research and development of compounds to regress atherosclerotic plaque, will be a presenting company at the Rodman & Renshaw 14th Annual Healthcare and Global Investment Conference to be held in New York City from September 9 -11, 2012 at the Waldorf-Astoria. Mark Selawski, CFO of AtheroNova, will present at 3:15pm ET on Tuesday, September 11.
Mr. Selawski will discuss exciting near term milestones for AHRO-001, the Company's lead compound for the regression of atherosclerotic plaque, as well as the Company's pipeline and development plans.
In addition to the presentation, Mr. Selawski will be available to meet with analysts, industry executives and investors in one-on-one meetings. Those interested in meeting with Mr. Selawski for a one-on-one discussion during the Conference are encouraged to contact the Company directly at email@example.com.
AtheroNova Inc., through its wholly-owned subsidiary, AtheroNova Operations, Inc., is an early stage biotech company focused on discovery, research, development and licensing of novel compounds to reduce or regress atherosclerotic plaque deposits. The Company's focus on compounds to reduce or eliminate atherosclerotic plaque deposits addresses the most lucrative segments of the multi-billion dollar prescription drug market: cardiovascular disease and stroke prevention. www.AtheroNova.com
Except for historical information contained herein, the statements in this release are forward-looking and made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are inherently unreliable and actual results may differ materially. Exa
|SOURCE AtheroNova Inc.|
Copyright©2012 PR Newswire.
All rights reserved